Skip to content
Review Open access

PrimeKG-Plus: a refreshed and rare-disease-enriched precision medicine knowledge graph

Jul 2026 · bioRxiv · 0 citations
Biology

TL;DR

PrimeKG-Plus restores the temporal relevance of PrimeKG, providing an updated resource for drug repurposing, rare-disease research, and downstream machine-learning applications.

Abstract

Background Disease-centered knowledge graphs (KGs) support drug repurposing and precision medicine research, yet many remain static after release while primary databases and literature continue to expand. PrimeKG (Precision Medicine Knowledge Graph) is a widely used multimodal KG providing a holistic view of diseases. However, its public release reflects a June 2021 data cutoff, omitting several years of subsequent data growth. This lag is especially consequential for rare diseases, where mechanistic and therapeutic evidence often remains scattered across publications rather than structured resources. Finding We present PrimeKG-Plus, a refreshed, rare-disease–enriched release of PrimeKG, rebuilt from all twenty original data resources updated to their December 2025 releases and three additional resources: OpenTargets, RepurposeDrugs, and nSIDES. Beyond synchronizing biomedical databases, PrimeKG-Plus captures approximately five years of previously unavailable rare-disease knowledge from the biomedical literature, curated from 637 PubMed abstracts and PubMed Central full-text articles using a language-model-assisted workflow focused on four rare neurological disorders: Canavan disease, Niemann–Pick disease type C, Tay–Sachs disease, and Batten disease. Extracted relations were refined through entity normalization, UMLS synonym mapping, embedding-based similarity ranking, and human expert review. Network topology analysis showed improved indirect drug–disease connectivity across three to six hops and added 447,288 drug–protein–disease paths linking previously unreachable drug–disease pairs. Temporal validation using drug approval records identified 55 molecular entities approved after the original PrimeKG June 2021 cutoff, 46 of which were absent from the original graph. Conclusion PrimeKG-Plus restores the temporal relevance of PrimeKG, providing an updated resource for drug repurposing, rare-disease research, and downstream machine-learning applications.

Read PDF

Similar papers

Open access Oct 2026

KRAKEN: A provenance-tracked knowledge graph for multiomic and wellness research

KRAKEN (Knowledge Research & Analysis Kit for Evidence Networks) addresses this gap by integrating existing graphs with specialized sources such as RefMet, LIPID MAPS, NIH Common Data Elements, Polygenic Score Catalog, and derived wellness measures including biological age and biological BMI.

Amy K. Glen, D. Witherington, Trent Leslie et al. · 0 citations
Open access Aug 2026

Every Cure Knowledge Graph: A Unified Biomedical Knowledge Graph for Drug Repurposing

EC-KG is an interoperable, provenance-first KG which integrates RTX-KG2, ROBOKOP, and PrimeKG at the network-level, encapsulating over 7 million nodes and 81 million edges from 95 primary data sources, and has improved coverage of core biomedical entities, and captures complex biomedical mechanisms within its topology.

Piotr Kaniewski, E. K. Carter, Daniel J. Rhodes et al. · 0 citations
Open access Sep 2026

LLM-enabled Natural History Study Analysis to Support Rare Disease Research

Background: Rare diseases affect an estimated 300 million people worldwide, yet the research needed to guide diagnosis and treatment is often fragmented across multiple unstructured literature sources. Natural history studies (NHS) are a key source of this evidence, but manually extracting structured information from N...

Kevin Li, E. Sid, Qian Zhu · 0 citations
Open access Aug 2026

Unveiling the depth of the knowledge gap in the Universe of Rare Diseases: the PLUTO mission

An extensive European database of non-oncologic rare diseases was established, enabling the identification of five distinct groups that reflect progressive stages of knowledge generation and drug development, highlighting a substantial knowledge and development gap across the rare disease landscape.

D. Ardigò, Francesco Bianchi, Maria Cristina Bosio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.